Skip to main content

US ClosedU.S. Closed

REPL: Replimune Group, Inc. Stock Analysis | finqOS

Healthcare · Biotechnology

Replimune Group, Inc. is a biotechnology enterprise dedicated to pioneering oncolytic immuno-gene therapies aimed at treating various cancers.

52W Range

96thpctl

Volume

0.38×avg

Market Cap

1.30BUSD

P/E Ratio

-4.9TTM

Div Yield

-ann

Loading chart data...

Current StateState loading

Replimune Group, Inc.

REPLNASDAQ Global Select·USD·Closed

Replimune Group, Inc.

REPLNASDAQ·USD·Closed

$15.50

−0.64%

$15.50

−$0.10 (0.64%)

52W Range

96thpctl

Volume

0.38×avg

Mkt Cap

1.30BUSD

P/E

-4.9TTM

Div Yield

–ann